National Institute on Drug Abuse; Notice of Closed Meetings, 4421 [2013-01100]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 14 / Tuesday, January 22, 2013 / Notices
https://ntp.niehs.nih.gov/go/roc12). The
13th RoC is under development. For
each listed substance, the RoC contains
a substance profile, which provides
information on: Cancer studies that
support the listing—including those in
humans, animals, and studies on
possible mechanisms of action—
information about potential sources of
exposure to humans, and current
Federal regulations to limit exposures.
Background Information on NTP Peer
Review Panels: NTP panels are
technical, scientific advisory bodies
established on an ‘‘as needed’’ basis to
provide independent scientific peer
review and advise the NTP on agents of
public health concern, new/revised
toxicological test methods, or other
issues. These panels help ensure
transparent, unbiased, and scientifically
rigorous input to the program for its use
in making credible decisions about
human hazard, setting research and
testing priorities, and providing
information to regulatory agencies about
alternative methods for toxicity
screening. The NTP welcomes
nominations of scientific experts for
upcoming panels. Scientists interested
in serving on an NTP panel should
provide a current curriculum vitae to
the FOR FURTHER INFORMATION CONTACT.
The authority for NTP panels is
provided by 42 U.S.C. 217a; section 222
of the Public Health Service (PHS) Act,
as amended. The panel is governed by
the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), which
sets forth standards for the formation
and use of advisory committees.
Dated: January 16, 2013.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2013–01242 Filed 1–18–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
tkelley on DSK3SPTVN1PROD with
National Institute on Drug Abuse;
Notice of Closed Meetings
[FR Doc. 2013–01100 Filed 1–18–13; 8:45 am]
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
18:11 Jan 18, 2013
Jkt 229001
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Development of Predictive In vivo Screening
Systems for Phenotypic Drug Discovery
(7786).
Date: January 25, 2013.
Time: 1:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Blvd., Room 4238, MSC 9550, Bethesda, MD
20892–9550, 301–402–6626,
gm145a@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; SBIR
Topic 148 Review Meeting (4418)
Date: January 30, 2013.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852,
Contact Person: Jose F. Ruiz, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, Room 4228, MSC 9550,
6001 Executive Blvd., Bethesda, MD 20892–
9550, (301) 451–3086, ruizjf@nida.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: January 15, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
VerDate Mar<15>2010
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
4421
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract and grant
proposals and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the contract proposals, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; Therapeutics Discovery.
Date: February 13–14, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health/
NCATS/OR, Democracy 1, Room 1080, 6701
Democracy Blvd., Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Barbara J. Nelson, Ph.D.,
Scientific Review Officer, Office of Grants
Management & Scientific Review, National
Center for Advancing Translational Sciences
(NCATS), National Institutes of Health, 6701
Democracy Blvd., Room 1080, 1 Dem. Plaza,
Bethesda, MD 20892–4874, 301–435–0806,
nelsonbj@mail.nih.gov.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; TRND–1.
Date: February 28–March 1, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Guo He Zhang, Ph.D.,
MPH, Scientific Review Officer, Office of
Grants Management & Scientific Review,
National Center for Advancing Translational
Sciences (NCATS), National Institutes of
Health, 6701 Democracy Blvd., Democracy 1,
Room 1064, Bethesda, MD 20892–4874, 301–
435–0812, zhanggu@mail.nih.gov.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; TRND–3.
Date: March 13–14, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Sheri A. Hild, Scientific
Review Officer, Office of Grants Management
& Scientific Review, National Center for
Advancing Translational Sciences (NCATS),
National Institutes of Health, 6701
Democracy Blvd., Democracy 1, Room 1082,
Bethesda, MD 20892–4874, 301–435–0811,
hildsa@mail.nih.gov.
E:\FR\FM\22JAN1.SGM
22JAN1
]]>Agencies
[Federal Register Volume 78, Number 14 (Tuesday, January 22, 2013)]
[Notices]
[Page 4421]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01100]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Development of Predictive In vivo Screening Systems
for Phenotypic Drug Discovery (7786).
Date: January 25, 2013.
Time: 1:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892-9550, 301-402-6626, gm145a@nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; SBIR Topic 148 Review Meeting (4418)
Date: January 30, 2013.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852,
Contact Person: Jose F. Ruiz, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse, NIH,
Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550,
(301) 451-3086, ruizjf@nida.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: January 15, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-01100 Filed 1-18-13; 8:45 am]
BILLING CODE 4140-01-P
